Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Significant Decrease in Short Interest

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a large decline in short interest during the month of June. As of June 15th, there was short interest totalling 75,000 shares, a decline of 83.1% from the May 31st total of 445,000 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average daily volume of 1,295,400 shares, the days-to-cover ratio is presently 0.1 days.

Insider Transactions at Xilio Therapeutics

In other news, major shareholder Gilead Sciences, Inc. bought 485,250 shares of the company’s stock in a transaction dated Tuesday, April 2nd. The shares were purchased at an average price of $0.76 per share, for a total transaction of $368,790.00. Following the completion of the purchase, the insider now owns 7,345,473 shares in the company, valued at approximately $5,582,559.48. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 5.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Xilio Therapeutics

An institutional investor recently bought a new position in Xilio Therapeutics stock. PFG Investments LLC purchased a new position in Xilio Therapeutics, Inc. (NASDAQ:XLO) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 30,000 shares of the company’s stock, valued at approximately $32,000. PFG Investments LLC owned 0.09% of Xilio Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 54.29% of the company’s stock.

Xilio Therapeutics Price Performance

XLO stock opened at $0.94 on Friday. The stock has a market capitalization of $34.70 million, a P/E ratio of -0.37 and a beta of -0.07. Xilio Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.94. The business has a fifty day moving average price of $1.06 and a 200-day moving average price of $0.87.

Xilio Therapeutics (NASDAQ:XLO) last posted its earnings results on Tuesday, May 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.29). As a group, analysts anticipate that Xilio Therapeutics will post -1.48 earnings per share for the current year.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.